Risk-Adapted therapy for clinical stage I-II Hodgkin's disease: 7-Year results of radiotherapy alone for low-risk disease, and ABVD and radiotherapy for high-risk disease

Clinical Oncology

Volumn 12, Issue 5, 2000, Pages 278-288

  MacKenzie, R G ^a,b   Franssen, E ^a   Wong, R ^a   Sawka, C ^a   Berinstein, N ^a   Cowan, D H ^a   Senn, J ^a   Poldre, P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Chemotherapy; Clinical stage I II; Complications; Hodgkin's disease; Radiotherapy; Risk adapted therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AVASCULAR NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; FATALITY; FEMALE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; NEUTROPENIA; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; SARCOMA; SCLEROSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0033693626     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2000.9174     Document Type: Article

References (65)

1. Boice JD. Second cancer after Hodgkin's disease - the price of success? J Natl Cancer Inst 1993;85:4-5.
2. Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: a report from the International Data Base on Hodgkin's disease. Semin Oncol 1990;17:758-68.
3. Henry-Amar M, Somers R. Long term survival in early stage Hodgkin's disease: the EORTC experience. In: Somers R, Henry-Amar M, Meerwaldt JH, et al., editors. Treatment strategy in Hodgkin's disease. Colloque: John Libbey Eurotext, 1990:151-66.
4. Kaldor JM. Second malignancies following Hodgkin's disease. In: Somers R, Henry-Amar M, Meerwaldt JH, et al., editors. Treatment strategy in Hodgkin's disease. Colloque: John Libbey Eurotext, 1990:139-50.
5. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996;6:225-42.
6. Abrahamsen AF, Hannisdal E, Nome O, et al. Clinical Stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol 1996;7:145-50.
7. Carde P, Burgers JM, Henry-Amar M, et al. Clinical Stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988;6:239-52.
8. Gospodarowicz MK, Sutcliffe SB, Bergsagel DE, et al. Radiation therapy in clinical Stage I and II Hodgkin's disease. Eur J Cancer 1992;28A:1841-6.
9. Horwich A, Easton D, Nogueira-Costa R, et al. An analysis of prognostic factors in early stage Hodgkin's disease. Radiother Oncol 1986;7:95-106.
10. Mauch PM, Tarbell N, Weinstein H, et al. Stage I and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988;6:1576-83.
11. Meerwaldt JH, Van Glabbeke M, Vaughan Hudson B. Prognostic factors for Stage I and II Hodgkin's disease. In: Somers R, Henry-Amar M, Meerwaldt JH, et al., editors. Treatment strategy in Hodgkin's disease. Colloque: John Libbey Eurotext, 1990:37-50.
12. Sears JD, Greven KM, Ferree CR, et al. Analysis of outcome, prognostic factors, and long-term complications. Cancer 1997;79:145-51.
13. Specht L, Nordentoft AM, Cold S, et al. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 1988;61:1719-27.
14. Thar TL, Million RR, Hausner RJ, et al. Hodgkin's disease, Stages I and II: relationship of recurrence to size of disease, radiation dose, and number of sites involved. Cancer 1979;43:1101-5.
15. Tubiana M, Henry-Amar M, Van der Werf-Messing B, et al. A multivariate analysis of prognostic factors in early stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985;11:23-30.
16. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical Stages I and II Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989;73:47-56.
17. Noordijk EM, Carde P, Mandard AM, et al. Preliminary results of the EORTCGPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994;5(2 Suppl 2):S107-12.
18. Sutcliffe SB, Gospodarowicz MK, Bergsagel DE, et al. Prognostic groups for management of localized Hodgkin's disease. J Clin Oncol 1985;3:393-401.
19. Kaplan E, Meier T. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. SAS/STAT User's Guide. Cary, NC: SAS Institute, 1989.
21. Hanks GE, Kinzie JJ, MacLean CJ. Patterns of care outcome studies in Hodgkin's disease: Hodgkin's disease relapse rates and adequacy of portals. Cancer 1983;52:2223-6.
22. Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor irradiation and complications. Cancer 1976;37:2812-25.
23. Schewe K, Reavis J, Kun L, et al. Total dose, fraction size and tumor volume in the local control of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1988;15:25-8.
24. Brincker H, Bentzen SM. A re-analysis of available dose-response data in Hodgkin's disease. Radiother Oncol 1994;30:227-30.
25. Mendenhall NP, Rodrigue LL, Moore-Higgs GJ, et al. The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in-field disease control. Int J Radiat Oncol Biol Phys 1999;44:551-61.
26. Boivin J, Hutchison GB, Lubin JH, et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992;69:1241-7.
27. Cosset JM, Henry-Amar M, Pellae-Cosset B, et al. Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys 1991;21:447-9.
28. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment for Hodgkin's disease. JAMA 1993;270:1949-55.
29. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993;11:1208-15.
30. Vijayakumar S, Myrianthopoulos LC. An updated doseresponse analysis in Hodgkin's disease. Radiother Oncol 1992;24:1-13.
31. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21 year Seattle experience. J Clin Oncol 1993;11:234250.
32. Gianni AM, Sienna S, Bregni M, et al. High dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease: a 6-year update. Ann Oncol 1993;10:889-91.
33. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-13.
34. Jagannath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989;7:179-85.
35. Mundt AJ, Sibley G, Hallahan D, et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 1995;33:261-70.
36. Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/ refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996;36:3-12.
37. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment for Hodgkin's disease. N Engl J Med 1991;325:599-605.
38. Sears JD, Greven KM, Ferree CR, et al. Definitive irradiation in the treatment of Hodgkin's disease. Cancer 1997;79:145-51.
39. Barton M, Boyages J, Crennan E, et al. Radiation therapy for early stage Hodgkin's disease: Australasian patterns of care. Int J Radiat Oncol Biol Phys 1995;31:227-36.
40. Boivin J, Hutchison GB, Zauber AG, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995;87:732-41.
41. Robinson BA, Colls BM, Fitzharris BM, et al. Second malignant neoplasms in patients with Hodgkin's disease. Aust N Z J Med 1994;24:368-73.
42. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318:76-81.
43. Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986;4:830-7.
44. Lipton JH, Gospodarowicz M, Reingold S. Acute myeloid leukemia following radiotherapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Hematol Oncol 1996;14:29-31.
45. Fuller L, Hutchison G. Collaborative clinical trial for Stage I and II Hodgkin's disease: significance of mediastinal and nonmediastinal disease in laparotomy-and non-laparotomy-staged patients. Cancer Treat Rep 1982;66:775-87.
46. Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease 1962-1984. Int J Radiat Oncol Biol Phys 1985;11:5-22.
47. Haybittle JL, Hayhoe FG, Easterling MJ, et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985;i:967-72.
48. Farah R, Ultmann J, Griem M, et al. Extended mantle radiation therapy for pathologic Stage I and II Hodgkin's disease. J Clin Oncol 1988;6:1047-52.
49. Zanini M, Viviani S, Santoro A, et al. Extended-field radiotherapy in favorable Stage IAIIA Hodgkin's disease (prognostic role of stage). Int J Radiat Oncol Biol Phys 1994;30:813-9.
50. Vlachaki MT, Ha CS, Hagemeister FB, et al. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys 1997;39:609-16.
51. Anderson H, Crowther D, Deakin DP, et al. A randomized study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10 year follow-up. Ann Oncol 1991;2:49-54.
52. Jones SE, Coltman CA, Grozea PN, et al. Conclusions from clinical trials of the Southwest Oncology Group. Cancer Treat Rep 1982;66:847-53.
53. Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol 1991;9:906-17.
54. Nissen N, Nordentoft A. Radiotherapy versus combined modality treatment of Stage I and II Hodgkin's disease. Cancer Treat Rep 1982;66:799-803.
55. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for Stage I-II Hodgkin's disease. J Natl Cancer Inst 1988;80:1466-73.
56. Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin's disease. Eur J Cancer 1992;28A:1847-50.
57. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11:2258-72.
58. Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997;79:1203-10.
59. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment for Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31.
60. Biti G, Cellai E, Magrini S, et al. Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 1994;29:25-31.
61. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312-25.
62. Diehl V, Pfreundschuh M, Loffler M, et al. Cooperative trials of Hodgkin's lymphoma in the Federal Republic of Germany. J Cancer Res Clin Oncol 1990;116:106-8.
63. Duhmke E, Diehl V, Loeffler M, et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 1996;36:305-10.
64. Biti GP, Cimino G, Cartoni C, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic Stage I-II A Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 1992;10:378-82.
65. Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-anlysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 1998;16:830-43.